The Efficacy of CAPCT in Patients With PTCL

NCT07746245 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-Cell Lymphoma

Interventions

DRUG: Chidamide
DRUG: Azacitidine (AZA)
DRUG: Prednisone
DRUG: Cyclophosphamide
DRUG: Thalidomide (100mg)

Sponsor

The First Affiliated Hospital with Nanjing Medical University